Cargando…
The Outcome of Chemotherapy for Metastatic Extramammary Paget’s Disease
The efficacy and survival impact of conventional chemotherapies for metastatic extramammary Paget’s disease (EMPD) have not been fully elucidated. This study examined the long-term outcome of chemotherapy for this indication. We conducted a retrospective review of 21 patients with distant metastatic...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918098/ https://www.ncbi.nlm.nih.gov/pubmed/33673310 http://dx.doi.org/10.3390/jcm10040739 |
_version_ | 1783657850657046528 |
---|---|
author | Hashimoto, Hiroki Kaku-Ito, Yumiko Furue, Masutaka Ito, Takamichi |
author_facet | Hashimoto, Hiroki Kaku-Ito, Yumiko Furue, Masutaka Ito, Takamichi |
author_sort | Hashimoto, Hiroki |
collection | PubMed |
description | The efficacy and survival impact of conventional chemotherapies for metastatic extramammary Paget’s disease (EMPD) have not been fully elucidated. This study examined the long-term outcome of chemotherapy for this indication. We conducted a retrospective review of 21 patients with distant metastatic EMPD (14 patients treated with chemotherapy and 7 patients treated without chemotherapy). The response rate of chemotherapy and patient survival were statistically analyzed. Among the 14 patients treated with chemotherapy, 12, 1, and 1 patient received docetaxel, paclitaxel, and low-dose 5-fluorouracil plus cisplatin, respectively, as the first-line treatment. The response rate was 50.0% (7/14), and the disease control rate was 64.3% (9/14). The median progression-free survival (PFS) and overall survival (OS) were 16.8 and 27.9 months, respectively. Multivariate analyses revealed that chemotherapy was a significant factor for prolonged PFS (hazard ratio (HR) 0.22, p = 0.038) but not for OS (HR = 1.71, p = 0.54). Ten patients (71.4%) had severe (grade 3 or 4) hematological adverse events. Although conventional chemotherapy improved PFS, we failed to show a significantly improved OS. Considering the frequent adverse events of conventional chemotherapy, targeted therapy may become a mainstay for the treatment of metastatic EMPD. |
format | Online Article Text |
id | pubmed-7918098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79180982021-03-02 The Outcome of Chemotherapy for Metastatic Extramammary Paget’s Disease Hashimoto, Hiroki Kaku-Ito, Yumiko Furue, Masutaka Ito, Takamichi J Clin Med Article The efficacy and survival impact of conventional chemotherapies for metastatic extramammary Paget’s disease (EMPD) have not been fully elucidated. This study examined the long-term outcome of chemotherapy for this indication. We conducted a retrospective review of 21 patients with distant metastatic EMPD (14 patients treated with chemotherapy and 7 patients treated without chemotherapy). The response rate of chemotherapy and patient survival were statistically analyzed. Among the 14 patients treated with chemotherapy, 12, 1, and 1 patient received docetaxel, paclitaxel, and low-dose 5-fluorouracil plus cisplatin, respectively, as the first-line treatment. The response rate was 50.0% (7/14), and the disease control rate was 64.3% (9/14). The median progression-free survival (PFS) and overall survival (OS) were 16.8 and 27.9 months, respectively. Multivariate analyses revealed that chemotherapy was a significant factor for prolonged PFS (hazard ratio (HR) 0.22, p = 0.038) but not for OS (HR = 1.71, p = 0.54). Ten patients (71.4%) had severe (grade 3 or 4) hematological adverse events. Although conventional chemotherapy improved PFS, we failed to show a significantly improved OS. Considering the frequent adverse events of conventional chemotherapy, targeted therapy may become a mainstay for the treatment of metastatic EMPD. MDPI 2021-02-12 /pmc/articles/PMC7918098/ /pubmed/33673310 http://dx.doi.org/10.3390/jcm10040739 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hashimoto, Hiroki Kaku-Ito, Yumiko Furue, Masutaka Ito, Takamichi The Outcome of Chemotherapy for Metastatic Extramammary Paget’s Disease |
title | The Outcome of Chemotherapy for Metastatic Extramammary Paget’s Disease |
title_full | The Outcome of Chemotherapy for Metastatic Extramammary Paget’s Disease |
title_fullStr | The Outcome of Chemotherapy for Metastatic Extramammary Paget’s Disease |
title_full_unstemmed | The Outcome of Chemotherapy for Metastatic Extramammary Paget’s Disease |
title_short | The Outcome of Chemotherapy for Metastatic Extramammary Paget’s Disease |
title_sort | outcome of chemotherapy for metastatic extramammary paget’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918098/ https://www.ncbi.nlm.nih.gov/pubmed/33673310 http://dx.doi.org/10.3390/jcm10040739 |
work_keys_str_mv | AT hashimotohiroki theoutcomeofchemotherapyformetastaticextramammarypagetsdisease AT kakuitoyumiko theoutcomeofchemotherapyformetastaticextramammarypagetsdisease AT furuemasutaka theoutcomeofchemotherapyformetastaticextramammarypagetsdisease AT itotakamichi theoutcomeofchemotherapyformetastaticextramammarypagetsdisease AT hashimotohiroki outcomeofchemotherapyformetastaticextramammarypagetsdisease AT kakuitoyumiko outcomeofchemotherapyformetastaticextramammarypagetsdisease AT furuemasutaka outcomeofchemotherapyformetastaticextramammarypagetsdisease AT itotakamichi outcomeofchemotherapyformetastaticextramammarypagetsdisease |